MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Where are LVADs headed in the future?

Where are LVADs headed in the future?

By

Abbott HeartMate 3 LVAD LVADs left ventricular assist devices
The HeartMate 3 LVAD. [Image courtesy of LVAD]
Abbott (NYSE:ABT) became the dominant provider of left ventricular assist devices (LVADs) after Medtronic’s decision last year to leave the market.

The Abbott HeartMate 3‘s advantages include its Full MagLev flow technology — which involves a free-floating magnetically levitated rotor that prevents surface-to-surface contact that could cause blood trauma. In addition, system batteries provide up to 17 hours of uninterrupted power, and the LVAD’s creators designed the system’s HeartMate Touch communications system to be intuitive and user-friendly.

Join us at DeviceTalks Boston on May 10-11, 2022, and find out where top Abbott officials would like to take LVADs next to better sustain heart failure patients’ lives.

Abbott officials on the panel include Chris Cotter, principal R&D engineer, Chad Dague, staff systems engineer, and Kevin Bourque, VP of R&D.

(Go to DeviceTalks Boston’s site to register!) 

 

 

More recent news

About Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at [email protected].